Evidence map›Paper›PMID 29259341›Full record

ArticleScientific reports2017

Impact of the G84E variant on HOXB13 gene and protein expression in formalin-fixed, paraffin-embedded prostate tumours.

Liesel M FitzGerald, Kelsie Raspin, James R Marthick, Matt A Field, Roslyn C Malley, Russell J Thomson, Nicholas B Blackburn, Annette Banks, Jac C Charlesworth, Shaun Donovan and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Liesel M FitzGeraldMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 7000, Australia.
Kelsie RaspinMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 7000, Australia.ORCID 0000-0001-8463-6820
James R MarthickMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 7000, Australia.
Matt A FieldAustralian Institute of Tropical Health and Medicine, James Cook University, Cairns, Qld, 4878, Australia.ORCID 0000-0003-0788-6513
Roslyn C MalleyRoyal Hobart Hospital, Hobart, TAS, 7000, Australia.
Russell J ThomsonWestern Sydney University, Sydney, NSW, 2150, Australia.
Nicholas B BlackburnMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 7000, Australia.ORCID 0000-0002-9774-1539
Annette BanksMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 7000, Australia.
Jac C CharlesworthMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 7000, Australia.
Shaun DonovanHobart Pathology, Hobart, TAS, 7000, Australia.
Joanne L DickinsonMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 7000, Australia. jo.dickinson@utas.edu.au.ORCID 0000-0003-4621-1703
University of Tasmania · AUAustralian National University · AURoyal Hobart Hospital · AUWestern Sydney University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The HOXB13 G84E variant is associated with risk of prostate cancer (PCa), however the role this variant plays in PCa development is unknown. This study examined 751 cases, 450 relatives and 355 controls to determine the contribution of this variant to PCa risk in Tasmania and investigated HOXB13 gene and protein expression in tumours from nine G84E heterozygote variant and 13 wild-type carriers. Quantitative PCR and immunohistochemistry showed that HOXB13 gene and protein expression did not differ between tumour samples from variant and wild-type carriers. Allele-specific transcription revealed that two of seven G84E carriers transcribed both the variant and wild-type allele, while five carriers transcribed the wild-type allele. Methylation of surrounding CpG sites was lower in the variant compared to the wild-type allele, however overall methylation across the region was very low. Notably, tumour characteristics were less aggressive in the two variant carriers that transcribed the variant allele compared to the five that did not. This study has shown that HOXB13 expression does not differ between tumour tissue of G84E variant carriers and non-carriers. Intriguingly, the G84E variant allele was rarely transcribed in carriers, suggesting that HOXB13 expression may be driven by the wild-type allele in the majority of carriers.

Indexed as

AllelesCase-Control StudiesCohort StudiesDNA MethylationFormaldehydeGene ExpressionGenetic Predisposition to DiseaseGenetic VariationGenotypeHeterozygoteHomeodomain ProteinsHumansMaleParaffin EmbeddingProstatic NeoplasmsRisk FactorsFormaldehydeHomeodomain ProteinsHOXB13 protein, human

Identifiers

PMID29259341
PMCPMC5736598
OpenAlexW2774456045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.